WO2025261457 - MEDICAL USE OF COMBINATION OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST AND SGLT-2 INHIBITOR
National phase entry is expected:
Publication Number
WO/2025/261457
Publication Date
26.12.2025
International Application No.
PCT/CN2025/102236
International Filing Date
20.06.2025
Title **
[English]
MEDICAL USE OF COMBINATION OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST AND SGLT-2 INHIBITOR
[French]
UTILISATION MÉDICALE D'UNE COMBINAISON D'UN ANTAGONISTE DU RÉCEPTEUR DE L'ENDOTHÉLINE A (ETA) ET D'UN INHIBITEUR DE SGLT-2
[Chinese]
内皮素A(ETA)受体拮抗剂联用SGLT-2抑制剂的医药用途
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
XIAO, Ying
MU, Shengmei
DUAN, Zhenfang
TANG, Hao
XING, Wei
LU, Yinsuo
WU, Junjun
Priority Data
202410818535.3
21.06.2024
CN
202410971020.7
18.07.2024
CN
202411294047.3
13.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1799 | |
| EPO | Filing, Examination, Granting | 11600 | |
| Japan | Filing, Examination, Granting | 2150 | |
| South Korea | Filing, Examination, Granting | 2107 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,396
Contact Us
Abstract[English]
A pharmaceutical composition comprising an endothelin A (ETA) receptor antagonist and an SGLT-2 inhibitor and use thereof in the preparation of a drug for preventing and/or treating a disease selected from nephropathy and hypertension, wherein the ETA receptor antagonist is a compound of formula (I) or a salt thereof, and the SGLT-2 inhibitor is selected from dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin, and salts thereof. (I)[French]
L'invention concerne une composition pharmaceutique comprenant un antagoniste du récepteur de l'endothéline A (ETA) et un inhibiteur de SGLT-2 et son utilisation dans la préparation d'un médicament pour la prévention et/ou le traitement d'une maladie sélectionnée parmi la néphropathie et l'hypertension, l'antagoniste du récepteur ETA étant un composé de formule (I) ou un sel de celui-ci, et l'inhibiteur de SGLT-2 étant choisi parmi la dapagliflozine, l'empagliflozine, la canagliflozine et l'ertugliflozine, et leurs sels. (I)[Chinese]
一种包含内皮素A(ETA)受体拮抗剂和SGLT-2抑制剂的药物组合物及其在制备用于预防和/或治疗选自肾病和高血压的疾病的药物中的用途，其中内皮素A(ETA)受体拮抗剂为式（I）化合物或其盐，SGLT-2抑制剂选自达格列净、恩格列净、卡格列净和艾托格列净及其盐， (I)